Abstract 98P
Background
Cell-free DNA (cfDNA) consists of circulating DNA fragments originating from cells throughout the body. It can be found in plasma and urine and is under heavy investigation for its potential to detect cancer both early, and as a minimally invasive biopsy. DNA methylation is strongly associated with tissue and cell type, and in the context of cancer, it is often significantly altered. Tumour derived cfDNA has been shown to contain tumour specific methylation patterns. In this study, we attempt to correlate tissue specific methylation with cfDNA methylation.
Methods
We extracted tumour tissue specific methylation signals from The Cancer Genome Association (TCGA) methylation data and used our RenovaroCube (AI platform) to mine tumour specific CpG sites from Illumina methylation array data. As Illumina methylation array data for liquid biopsies is scarce due to the high input requirements, we investigated an alternative methylation detection method: cell-free Methylation DNA ImmunoPrecipiation (cfMeDIP-seq). cfMeDIP-seq captures solely 5mC methylated cfDNA fragments, which are then sorted into 300bp windows. From 97 publicly available cfDNA plasma cfMeDIP samples (24 control, 23 CRC, 25 lung cancer, 25 BRCA) we extracted the 300bp windows containing mined TCGA CpG sites. Using random forest classifiers, we performed leave-one-out-cross-validations (LOOCV) for the classifcation of cancer types. We further validated the lung cancer model using a cfMeDIP-seq validation set (62 control, 55 lung cancer).
Results
From the TCGA data, we mined 86 NSCLC, 95 BRCA and 139 CRC specific CpG sites, resulting in 72, 74 and 121 300bp panels, respectively. The performance of the panels was evaluated through LOOCV, resulting in (Specificity/Sensitivity/Accuracy): NSCLC model: 0.96/0.59/0.75, BRCA model: 1.00/0.72/0.86, CRC model: 1.00/0.841/0.92. In the validation lung cancer dataset, we obtained a performance of 0.97/0.49/0.74.
Conclusions
It is possible to detect tissue specific methylation levels extracted from methylation array data using RenovaroCube platform in cfDNA using cfMeDIP-seq data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1802P - Cost-effectiveness study of atezolizumab (ATZ) vs. durvalumab (DUR) in elderly extensive disease small cell lung cancer (ED-SCLC) patients (pts): Real-world data (RWD) on first-line chemotherapy combined with immune-checkpoint inhibitors (Chemo-ICIs)
Presenter: Ken Yamamoto
Session: Poster session 07
1803P - Analysis of samples from the SCLC REACTION trial: Discovery of biomarkers to optimize treatment
Presenter: Pernelle Lavaud
Session: Poster session 07
1805P - PKD1L1 mutations in small cell lung cancer: A genomic signature for poor prognosis and drug susceptibility
Presenter: Ning Tang
Session: Poster session 07
Resources:
Abstract
1806P - Clinical characteristics and management of small cell lung cancer long survivors
Presenter: Elisa Gobbini
Session: Poster session 07
1807P - Spatial analyses revealed MMP7 as the biomarker of tumor boundary correlated with immune resistance in small cell lung cancer
Presenter: Le Tang
Session: Poster session 07
1809P - Validation of the lung inmune prognostic (LIPI) index in first-line immunotherapy treatment of small cell lung carcinoma
Presenter: Patricia Cruz Castellanos
Session: Poster session 07
1810P - MYC expression defines distinct transcriptomic landscape and affects response to DNA-damaging therapies in SCLC
Presenter: Caterina de Rosa
Session: Poster session 07